CybernaX presents extrahepatic delivery data at the RNA-Based Therapeutics & Vaccines Summit Asia
18 November 2025 — CybernaX took part in the RNA-Based Therapeutics & Vaccines Summit Asia in Incheon, South Korea, where Dr. Pengbo Guo presented Targeting Beyond the Liver — Achieving Organ-Specific Delivery with Next-Generation Lipid Libraries, Formulations and Payload Optimization. The session was listed on the official agenda as carrying new data.
The summit program listing for the CybernaX session, flagged as new data.
Image: Hanson Wade / World RNA Series.
Almost every approved LNP medicine goes to the liver, because that is where ApoE adsorption sends the particle. Getting anywhere else means changing the particle rather than the dose. The presentation walked through how CybernaX combines library-scale lipid screening with formulation and payload work to shift tissue tropism, and why doing so also widens the window between an effective dose and a tolerated one.
Themes covered included:
- Lipid nanoparticle design choices that govern organ-specific delivery
- AI-assisted and machine-learning screening of novel lipids with distinct organ tropism, improving efficacy while reducing toxicity to broaden the dosing window
- How current LNP engineering strategies and library designs hold up for effective extrahepatic targeting
The summit convened more than eighty RNA specialists from across Asia — CxO level, heads of R&D and CMC, and business development leads — with the aim of moving RNA modalities toward commercial reality faster.
About CybernaX
CybernaX Biotechnologies develops non-viral nucleic acid delivery technology, built on two lipid platforms: ELITE (CX Ionizable Lipid), an embodied-AI screened ionizable lipid library, and ENDURE (CX Stabilizing Lipid), a PEG-free monodisperse lipid built for long-term repeat dosing. The company licenses and co-develops its lipid platforms with biopharmaceutical and biotechnology partners worldwide.